- Home
- OABI vs FLC Comparison
OABI vs FLC Comparison
Compare OABI & FLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OABI
- FLC
- Stock Information
- Founded
- OABI 2012
- FLC 2003
- Country
- OABI United States
- FLC United States
- Employees
- OABI N/A
- FLC N/A
- Industry
- OABI Biotechnology: Pharmaceutical Preparations
- FLC Trusts Except Educational Religious and Charitable
- Sector
- OABI Health Care
- FLC Finance
- Exchange
- OABI Nasdaq
- FLC Nasdaq
- Market Cap
- OABI 227.4M
- FLC 186.8M
- IPO Year
- OABI N/A
- FLC N/A
- Fundamental
- Price
- OABI $1.66
- FLC $17.80
- Analyst Decision
- OABI Strong Buy
- FLC
- Analyst Count
- OABI 3
- FLC 0
- Target Price
- OABI $6.67
- FLC N/A
- AVG Volume (30 Days)
- OABI 595.9K
- FLC 37.8K
- Earning Date
- OABI 11-11-2025
- FLC 01-01-0001
- Dividend Yield
- OABI N/A
- FLC 6.64%
- EPS Growth
- OABI N/A
- FLC N/A
- EPS
- OABI N/A
- FLC N/A
- Revenue
- OABI $23,027,000.00
- FLC N/A
- Revenue This Year
- OABI N/A
- FLC N/A
- Revenue Next Year
- OABI $48.74
- FLC N/A
- P/E Ratio
- OABI N/A
- FLC N/A
- Revenue Growth
- OABI 6.05
- FLC N/A
- 52 Week Low
- OABI $1.22
- FLC $12.62
- 52 Week High
- OABI $4.87
- FLC $15.45
- Technical
- Relative Strength Index (RSI)
- OABI 49.38
- FLC 64.49
- Support Level
- OABI $1.58
- FLC $17.72
- Resistance Level
- OABI $1.72
- FLC $17.93
- Average True Range (ATR)
- OABI 0.08
- FLC 0.10
- MACD
- OABI 0.02
- FLC -0.02
- Stochastic Oscillator
- OABI 65.15
- FLC 42.86
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.
About FLC Flaherty & Crumrine Total Return Fund Inc
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.